abstract: The Workshop identified 48 unselected @entity1 with therapy-related @entity4 or @entity5 (t-MDS/t-AML) and inv(16), and 41 @entity1 with t(15;17) after chemotherapy (CT) and/or radiotherapy (RT) for a malignant or nonmalignant disease. The primary diseases were: @entity0 , 33 @entity1 ; @entity3 , 24 @entity1 ; various other solid @entity2 , 30 @entity1 ; and nonmalignant diseases, 2 @entity1 . The general type of previous therapy was RT only in 10 @entity1 with an inv(16) and in 12 @entity1 with a t(15;17), alkylating agents plus topoisomerase II inhibitors in 24 @entity1 with an inv(16) and in 18 @entity1 with a t(15;17), topoisomerase II inhibitors only in 5 @entity1 with an inv(16) and in 2 @entity1 with a t(15;17), alkylating agents only in 6 @entity1 in each subgroup, and other types of chemotherapy in 3 @entity1 in each subgroup. Most CT-treated @entity1 (69%) also received RT. The latency period to development of t-MDS/t-AML was short: a median of 22 months in @entity1 with inv(16) and 29 months in @entity1 with t(15;17). Twenty-six @entity1 (54%) with an inv(16) and 17 @entity1 (41%) with a t(15;17) had additional cytogenetic abnormalities, which were unrelated to age and survival in both subgroups. Trisomy of chromosomes 8, 21, and 22 and @entity6 ) were the most frequent additional abnormalities in the inv(16) subgroup, whereas +8, -5, and del(16q) were most frequent in the t(15;17) subgroup. The disease was overt t-AML in 38/48 @entity1 (79%) with an inv(16) and in 38/41 @entity1 (93%) with a t(15;17). Thirty-three of 39 intensively treated @entity1 (85%) with an inv(16) obtained a complete remission, whereas 24 of 35 intensively treated @entity1 (69%) with a t(15;17) obtained a complete remission. The median overall survival of intensively treated @entity1 was 29 months in both cytogenetic subgroups. In the inv(16) subgroup, @entity1 younger than 55 years of age had a longer survival when compared with older @entity1 (P = 0.006). The study supports the observation that t-MDS/t-AML with inv(16) and t(15;17) is often associated with prior therapy with topoisomerase II inhibitors; however, a notable finding was the high frequency of treatment with only radiotherapy, 29% of t(15;17) and 21% of inv(16). Response rates to intensive chemotherapy in this study were comparable to those of de novo disease.

title: Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related XXXX and @entity5 : report from an international workshop.

answer: @entity4


abstract: The Workshop identified 48 unselected @entity1 with therapy-related @entity4 or @entity5 (t-MDS/t-AML) and inv(16), and 41 @entity1 with t(15;17) after chemotherapy (CT) and/or radiotherapy (RT) for a malignant or nonmalignant disease. The primary diseases were: @entity0 , 33 @entity1 ; @entity3 , 24 @entity1 ; various other solid @entity2 , 30 @entity1 ; and nonmalignant diseases, 2 @entity1 . The general type of previous therapy was RT only in 10 @entity1 with an inv(16) and in 12 @entity1 with a t(15;17), alkylating agents plus topoisomerase II inhibitors in 24 @entity1 with an inv(16) and in 18 @entity1 with a t(15;17), topoisomerase II inhibitors only in 5 @entity1 with an inv(16) and in 2 @entity1 with a t(15;17), alkylating agents only in 6 @entity1 in each subgroup, and other types of chemotherapy in 3 @entity1 in each subgroup. Most CT-treated @entity1 (69%) also received RT. The latency period to development of t-MDS/t-AML was short: a median of 22 months in @entity1 with inv(16) and 29 months in @entity1 with t(15;17). Twenty-six @entity1 (54%) with an inv(16) and 17 @entity1 (41%) with a t(15;17) had additional cytogenetic abnormalities, which were unrelated to age and survival in both subgroups. Trisomy of chromosomes 8, 21, and 22 and @entity6 ) were the most frequent additional abnormalities in the inv(16) subgroup, whereas +8, -5, and del(16q) were most frequent in the t(15;17) subgroup. The disease was overt t-AML in 38/48 @entity1 (79%) with an inv(16) and in 38/41 @entity1 (93%) with a t(15;17). Thirty-three of 39 intensively treated @entity1 (85%) with an inv(16) obtained a complete remission, whereas 24 of 35 intensively treated @entity1 (69%) with a t(15;17) obtained a complete remission. The median overall survival of intensively treated @entity1 was 29 months in both cytogenetic subgroups. In the inv(16) subgroup, @entity1 younger than 55 years of age had a longer survival when compared with older @entity1 (P = 0.006). The study supports the observation that t-MDS/t-AML with inv(16) and t(15;17) is often associated with prior therapy with topoisomerase II inhibitors; however, a notable finding was the high frequency of treatment with only radiotherapy, 29% of t(15;17) and 21% of inv(16). Response rates to intensive chemotherapy in this study were comparable to those of de novo disease.

title: Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related @entity4 and XXXX : report from an international workshop.

answer: @entity5


abstract: Seventy-seven @entity1 were identified with Rare recurring (excluding 11q23, 21q22, inv(16), and t(15;17)) @entity6 among 511 @entity1 with treatment-related @entity7 and @entity8 accepted from centers in the United States, Europe, and Japan. The abnormality subsets included 3q21q26 (17 @entity1 ), 11p15 (17 @entity1 ), t(9;22)(q34;q11) (10 @entity1 ), 12p13 (9 @entity1 ), t(8;16)(p11;p13) (9 @entity1 ), and an "other" subset, which included t(6;9)(p23;q34) (3 @entity1 ), t(10;11)(p13;q13 approximately q21) (3 @entity1 ), t(1;17)(p36;q21) (2 @entity1 ), t(8;14)(q24;q32) (2 @entity1 ), t(11;19)(q13;q13) (2 @entity1 ), t(1;3)(p36;q21) (2 @entity1 ), and t(3;5)(q21;q31) (1 @entity1 ). Increased karyotypic complexity with additional balanced and unbalanced rearrangements was observed in 70% of cases. Among 54 cases with @entity6 were observed in 59%. The most frequent @entity2 were @entity0 (24 cases), @entity3 (14 cases), @entity5 (10 cases), and de novo @entity4 (5 cases). Thirty-seven @entity1 received alkylating agents plus topoisomerase II inhibitors with or without radiation therapy. The presenting diagnosis was t-AML in 47 cases, t-MDS in 23 cases (10 progressed to t-AML), and t- @entity4 in seven cases, five of whom had a t(9;22). The median latency time from initiation of original therapy to therapy-related disease diagnosis was quite long (69 months), and the overall median survival from the date of therapy-related disease diagnosis was very short (7 months). The 1-year survival rate was 34 +/- 7%, with no significant differences among subsets. Comparison with previously reported cases showed increased karyotypic complexity and adult presentation of pediatric-associated @entity6 .

title: Rare recurring balanced @entity6 in therapy-related XXXX and @entity8 : report from an international workshop.

answer: @entity7


abstract: Seventy-seven @entity1 were identified with Rare recurring (excluding 11q23, 21q22, inv(16), and t(15;17)) @entity6 among 511 @entity1 with treatment-related @entity7 and @entity8 accepted from centers in the United States, Europe, and Japan. The abnormality subsets included 3q21q26 (17 @entity1 ), 11p15 (17 @entity1 ), t(9;22)(q34;q11) (10 @entity1 ), 12p13 (9 @entity1 ), t(8;16)(p11;p13) (9 @entity1 ), and an "other" subset, which included t(6;9)(p23;q34) (3 @entity1 ), t(10;11)(p13;q13 approximately q21) (3 @entity1 ), t(1;17)(p36;q21) (2 @entity1 ), t(8;14)(q24;q32) (2 @entity1 ), t(11;19)(q13;q13) (2 @entity1 ), t(1;3)(p36;q21) (2 @entity1 ), and t(3;5)(q21;q31) (1 @entity1 ). Increased karyotypic complexity with additional balanced and unbalanced rearrangements was observed in 70% of cases. Among 54 cases with @entity6 were observed in 59%. The most frequent @entity2 were @entity0 (24 cases), @entity3 (14 cases), @entity5 (10 cases), and de novo @entity4 (5 cases). Thirty-seven @entity1 received alkylating agents plus topoisomerase II inhibitors with or without radiation therapy. The presenting diagnosis was t-AML in 47 cases, t-MDS in 23 cases (10 progressed to t-AML), and t- @entity4 in seven cases, five of whom had a t(9;22). The median latency time from initiation of original therapy to therapy-related disease diagnosis was quite long (69 months), and the overall median survival from the date of therapy-related disease diagnosis was very short (7 months). The 1-year survival rate was 34 +/- 7%, with no significant differences among subsets. Comparison with previously reported cases showed increased karyotypic complexity and adult presentation of pediatric-associated @entity6 .

title: Rare recurring balanced @entity6 in therapy-related @entity7 and XXXX : report from an international workshop.

answer: @entity8


abstract: Seventy-seven @entity1 were identified with Rare recurring (excluding 11q23, 21q22, inv(16), and t(15;17)) @entity6 among 511 @entity1 with treatment-related @entity7 and @entity8 accepted from centers in the United States, Europe, and Japan. The abnormality subsets included 3q21q26 (17 @entity1 ), 11p15 (17 @entity1 ), t(9;22)(q34;q11) (10 @entity1 ), 12p13 (9 @entity1 ), t(8;16)(p11;p13) (9 @entity1 ), and an "other" subset, which included t(6;9)(p23;q34) (3 @entity1 ), t(10;11)(p13;q13 approximately q21) (3 @entity1 ), t(1;17)(p36;q21) (2 @entity1 ), t(8;14)(q24;q32) (2 @entity1 ), t(11;19)(q13;q13) (2 @entity1 ), t(1;3)(p36;q21) (2 @entity1 ), and t(3;5)(q21;q31) (1 @entity1 ). Increased karyotypic complexity with additional balanced and unbalanced rearrangements was observed in 70% of cases. Among 54 cases with @entity6 were observed in 59%. The most frequent @entity2 were @entity0 (24 cases), @entity3 (14 cases), @entity5 (10 cases), and de novo @entity4 (5 cases). Thirty-seven @entity1 received alkylating agents plus topoisomerase II inhibitors with or without radiation therapy. The presenting diagnosis was t-AML in 47 cases, t-MDS in 23 cases (10 progressed to t-AML), and t- @entity4 in seven cases, five of whom had a t(9;22). The median latency time from initiation of original therapy to therapy-related disease diagnosis was quite long (69 months), and the overall median survival from the date of therapy-related disease diagnosis was very short (7 months). The 1-year survival rate was 34 +/- 7%, with no significant differences among subsets. Comparison with previously reported cases showed increased karyotypic complexity and adult presentation of pediatric-associated @entity6 .

title: Rare recurring balanced XXXX in therapy-related @entity7 and @entity8 : report from an international workshop.

answer: @entity6


abstract: Although @entity6 of the prostate ( @entity5 ) is typically present on biopsies in which there is also @entity3 of Gleason pattern 4 or 5 and an associated unfavorable outcome, there are limited studies on @entity5 in needle core biopsies or transurethral resections (TURP) with only a concomitant low-grade invasive component. There are differing opinions on incorporating @entity5 into the Gleason score in such cases. The aim of this study was to investigate clinical outcomes and radical prostatectomy (RP) findings in @entity0 with Gleason 3+3=6 and @entity5 on biopsy or TURP. We identified 73 @entity0 in our consult files (2001 to 2014) who had @entity5 and Gleason score 6 @entity2 on biopsy or TURP with no invasive higher Gleason grade component. Clinical follow-up information was available in 62 @entity0 . Treatment was RP in 14 @entity0 , radiation therapy in 31 @entity0 , @entity4 deprivation therapy in 1 @entity0 , and cryotherapy in 1 @entity0 . Four @entity0 were found to have metastatic disease at the time of diagnosis and were treated with chemotherapy. Eleven @entity0 underwent active surveillance after diagnosis, of which 6 were eventually treated for progressive disease. The 14 RP specimens were centrally reviewed, and 86% had extensive @entity5 present. The Gleason grades in these 14 RP cases were 3+3=6 in 21%, 3+4=7 in 36%, 4+3=7 in 29%, and 4+4=8 in 14%. Pathologic stage was pT2 in 36%, pT3a in 36%, and pT3b in 28%. After 3 years, there was a 20% actuarial rate of disease progression in @entity0 who underwent either RP or radiation therapy. In summary, most @entity0 with @entity5 on biopsy/TURP have aggressive @entity1 , even when the invasive @entity1 on biopsy is Gleason score 6. As a minority of @entity0 may only have Gleason 6 invasive @entity1 at RP and a favorable prognosis, we recommend that @entity5 on biopsy/TURP be reported separately and not assigned a Gleason score.

title: Prostate Biopsy Specimens With Gleason 3+3=6 and XXXX : Radical Prostatectomy Findings and Clinical Outcomes.

answer: @entity6


abstract: The beta3-adrenergic receptor is an integral membrane protein consisting of seven transmembrane domains. Unlike the beta1 and beta2 receptors, this subtype lacks the consensus phosphorylation sites required for desensitization by @entity1 kinases. Using the rodent specific beta3 agonist @entity5 , our initial data indicated that beta3 receptor-mediated @entity2 levels progressively decreased following daily oral doses of 5 mg/kg. Therefore, we initiated studies designed to delineate the possible mechanism(s) for this decreased response. Within 3 hours following a single oral dose of @entity5 , serum @entity2 levels and @entity4 (uncoupling protein) RNA levels were significantly increased whereas beta3 RNA levels were significantly decreased. @entity0 were dosed daily for 5 days with either vehicle or @entity5 (5 mg/kg, p.o.) and blood samples were collected for @entity2 analysis. Adipose tissue was excised for lipolysis and adenyl cyclase measurements. In addition, @entity4 and beta3 receptor RNA levels were assessed. No effect on adipocyte @entity3 -stimulated adenylyl cyclase activity was observed 3 hours following the initial dose of @entity5 . Although a slight decrease (approximately 25%) in adenylyl cyclase activity could be observed 24 hours following the initial dose, it wasn't until day 4 of dosing that a significant decrease (50%) was observed. In contrast, beta3- stimulated lipolysis in adipocytes from @entity5 -treated @entity0 was decreased 85% within 24 hours and this decrease persisted through four days of treatment. These data indicate that the lipolytic response to beta3 receptor activation is decreased after only a single oral dose of @entity5 , whereas receptor-mediated adenylyl cyclase activation, although initially unaffected, also desensitizes by day four of treatment.

title: Desensitization of beta3-adrenergic receptor-stimulated adenylyl cyclase activity and lipolysis in XXXX .

answer: @entity0


abstract: The syncytiotrophoblast, which is delineated by two polar membranes (the microvillous and the basal plasma membranes), is the main placental structural element controlling maternal-fetal exchanges. These studies of the full-term placenta were undertaken in order to determine whether the microvillous membranes, which are bathed by the maternal intervillous circulation, and basal plasma membrane, which lines the fetal blood capillaries, have binding sites for @entity2 . The microvillous and basal plasma membranes were purified and found to bind 125I- @entity2 with significantly different (p < 0.0001) Kd (0.51 and 1.02 nM, respectively). There were more available binding sites in the microvillous (4.4+/-0.3 pmol/mg protein) than in the basal (2.7+/-0.4 pmol/mg protein) plasma membranes (p < 0.0001). Both membranes contained three major (250, 135, and 130 kDa) 125I- @entity2 /binding-site protein complexes as determined by affinity cross-linking and PAGE. The 250-kDa band (type 2 IGF receptor) was the main band in the basal plasma membranes (46% total bound 125I- @entity2 ). The 135-kDa band (insulin-receptor alpha subunit) was the main one in the microvillous membranes (48% total bound 125I- @entity2 ). The amounts of 130-kDa band (type 1 IGF-receptor alpha subunit) in the two types of membranes were similar (30% total bound 125I- @entity2 ). Only @entity2 displaced 125I- @entity2 from the 250-kDa band, while 125I- @entity2 bound to the 135-kDa band was displaced by insulin, and ligand bound to the 130-kDa band was displaced by @entity1 . Thus there are IGF receptors in both types of membranes of syncytiotrophoblast in the @entity0 full-term placenta, and the distributions of the IGF and insulin receptors are asymmetrical. This may reflect the fact that they face and interact with two independent, different media. Maternal IGF may influence the syncytiotrophoblast by binding to receptors on the microvillous membranes, while fetal IGF may also influence syncytiotrophoblast functions by activating receptors in the basal plasma membranes.

title: Differential distribution of binding sites for 125I-insulin-like growth factor II on trophoblast membranes of XXXX term placenta.

answer: @entity0


abstract: The aim of the study was to determine the prognosis of @entity3 . 145 adults (96 @entity0 , 49 @entity0 ) with @entity3 during childhood were examined above age of 28 years (mean age was 37.6, SD: 5.9 years). The @entity0 filled out questionnaires about the @entity5 and @entity1 in their childhood, age at 18 years and at present. They all were physically examined and prick tested with 12 inhalant allergens. 43% of the @entity0 became symptom-free but 57% still had intermittent or persisting @entity6 while growing up. More @entity0 had intermittent @entity5 day (59%) and night (67%) symptoms than persisting ones (41 and 33%). The accompanying @entity1 in childhood did not definitely affect the prognosis of @entity3 . These are more frequent in the females, regarding before all the @entity2 . At the age of 18, the occurrence of @entity7 was more frequent than in childhood. The frequency of other @entity1 did not change significantly. Among @entity0 with @entity6 , moulds and cat hair @entity4 were more frequent than in the symptom-free group. The long-term prognosis of childhood @entity3 is relatively good, however only less than 50% of the @entity0 has become symptom-free. In most of the adult @entity0 the complaints are relatively mild. The indoor allergens may contribute to the occurrence of @entity6 .

title: [Changes in the symptoms of @entity3 and associated XXXX from childhood to adult age].

answer: @entity1


abstract: The aim of the study was to determine the prognosis of @entity3 . 145 adults (96 @entity0 , 49 @entity0 ) with @entity3 during childhood were examined above age of 28 years (mean age was 37.6, SD: 5.9 years). The @entity0 filled out questionnaires about the @entity5 and @entity1 in their childhood, age at 18 years and at present. They all were physically examined and prick tested with 12 inhalant allergens. 43% of the @entity0 became symptom-free but 57% still had intermittent or persisting @entity6 while growing up. More @entity0 had intermittent @entity5 day (59%) and night (67%) symptoms than persisting ones (41 and 33%). The accompanying @entity1 in childhood did not definitely affect the prognosis of @entity3 . These are more frequent in the females, regarding before all the @entity2 . At the age of 18, the occurrence of @entity7 was more frequent than in childhood. The frequency of other @entity1 did not change significantly. Among @entity0 with @entity6 , moulds and cat hair @entity4 were more frequent than in the symptom-free group. The long-term prognosis of childhood @entity3 is relatively good, however only less than 50% of the @entity0 has become symptom-free. In most of the adult @entity0 the complaints are relatively mild. The indoor allergens may contribute to the occurrence of @entity6 .

title: [Changes in the symptoms of XXXX and associated @entity1 from childhood to adult age].

answer: @entity3


abstract: We describe a @entity0 with a streptococcal @entity9 / @entity10 and @entity3 following an intramuscular injection with @entity8 . A @entity0 complaining of sore throat and @entity1 for two days and fever up to 38.5 degrees C for one day consulted her family physician. 75 mg of @entity8 were injected intramuscularly for symptomatic treatment. On the next day massive @entity4 at the injection site and a generalized erythema occurs and fever up to 38.5 degrees C persists. She is admitted to the local hospital for suspected @entity6 formation. Despite rapid antibiotic treatment a @entity5 develops. The @entity0 is transferred to a tertiary care hospital. An extensive debridement is performed and the antibiotic regimen changed to high dose @entity2 and @entity7 . The association of life threatening diseases due to Group A streptococci and non-steroidal anti-inflammatory drugs (NSAID) is well documented by several case reports. We believe there is no longer any need for intramuscular injections of NSAID. The rare but severe complications preclude further use of the intramuscular dosage in view of the availability of oral alternatives.

title: [Erythema and fever after XXXX i.m].

answer: @entity8


abstract: OBJECTIVE: Carotid angioplasty with stent placement is becoming an established treatment modality for @entity0 with high-risk carotid @entity4 . Unlike carotid endarterectomy, angioplasty causes direct mechanical dilation of the stenotic carotid artery and bulb. Stimulation of the sinus baroreceptors induces a reflexive response that consists of increased parasympathetic discharge and inhibition of sympathetic tone, which results in @entity5 and subsequent cardiogenic @entity3 . METHODS: At a single institution, the experience with 43 @entity0 treated from November 1994 to January 2000 with 47 angioplasty and stent procedures for occlusive @entity6 was retrospectively reviewed. Prophylactic temporary venous pacemakers were used to prevent @entity3 from possible angioplasty-induced @entity5 . Pacemakers were set to capture a heart rate decrease below 60 beats per minute. Variables analyzed included demographics, etiology of disease, side of the lesion, the presence of symptoms, history of @entity2 , percent @entity4 , type of stent used, number of dilations, pressure of dilation, and angioplasty balloon diameter. RESULTS: Ten @entity0 were excluded because pacemakers were not used during their angioplasty procedures, and these included three @entity1 and a lesion that was unrelated anatomically to the carotid sinus (petrous carotid). The remaining 37 procedures were performed in 33 @entity0 with a mean age of 67 years, and consisted of 17 @entity0 , 16 @entity0 , 20 right and 17 left-sided lesions. The pacemakers maintained a cardiac rhythm in 23 (62%) of the 37 procedures and in no case did the pacemaker fail to respond when activated. Recurrent (56%; 10 of 18), radiation-induced (78%; 7 of 9), and medically refractory carotid @entity4 (67%; 6 of 9) required intraprocedural pacing. Two @entity0 with recurrent @entity4 became @entity3 despite the aid of the pacing device but were not symptomatic. Seventy-nine percent (15 of 19) of symptomatic lesions and 57% (8 of 14) of nonsymptomatic lesions required pacing, which was statistically significant (P = 0.049). No @entity0 experienced an operative morbidity or mortality as a consequence of the temporary pacing devices. CONCLUSION: Angioplasty-induced @entity5 is a common condition, and it is more prevalent in radiation-induced @entity4 and with symptomatic lesions. Temporary venous demand pacing is a safe procedure and may prevent life-threatening, baroreceptor-induced @entity3 .

title: Prevention of carotid angioplasty-induced @entity5 and XXXX with temporary venous pacemakers.

answer: @entity3


abstract: OBJECTIVE: Carotid angioplasty with stent placement is becoming an established treatment modality for @entity0 with high-risk carotid @entity4 . Unlike carotid endarterectomy, angioplasty causes direct mechanical dilation of the stenotic carotid artery and bulb. Stimulation of the sinus baroreceptors induces a reflexive response that consists of increased parasympathetic discharge and inhibition of sympathetic tone, which results in @entity5 and subsequent cardiogenic @entity3 . METHODS: At a single institution, the experience with 43 @entity0 treated from November 1994 to January 2000 with 47 angioplasty and stent procedures for occlusive @entity6 was retrospectively reviewed. Prophylactic temporary venous pacemakers were used to prevent @entity3 from possible angioplasty-induced @entity5 . Pacemakers were set to capture a heart rate decrease below 60 beats per minute. Variables analyzed included demographics, etiology of disease, side of the lesion, the presence of symptoms, history of @entity2 , percent @entity4 , type of stent used, number of dilations, pressure of dilation, and angioplasty balloon diameter. RESULTS: Ten @entity0 were excluded because pacemakers were not used during their angioplasty procedures, and these included three @entity1 and a lesion that was unrelated anatomically to the carotid sinus (petrous carotid). The remaining 37 procedures were performed in 33 @entity0 with a mean age of 67 years, and consisted of 17 @entity0 , 16 @entity0 , 20 right and 17 left-sided lesions. The pacemakers maintained a cardiac rhythm in 23 (62%) of the 37 procedures and in no case did the pacemaker fail to respond when activated. Recurrent (56%; 10 of 18), radiation-induced (78%; 7 of 9), and medically refractory carotid @entity4 (67%; 6 of 9) required intraprocedural pacing. Two @entity0 with recurrent @entity4 became @entity3 despite the aid of the pacing device but were not symptomatic. Seventy-nine percent (15 of 19) of symptomatic lesions and 57% (8 of 14) of nonsymptomatic lesions required pacing, which was statistically significant (P = 0.049). No @entity0 experienced an operative morbidity or mortality as a consequence of the temporary pacing devices. CONCLUSION: Angioplasty-induced @entity5 is a common condition, and it is more prevalent in radiation-induced @entity4 and with symptomatic lesions. Temporary venous demand pacing is a safe procedure and may prevent life-threatening, baroreceptor-induced @entity3 .

title: Prevention of carotid angioplasty-induced XXXX and @entity3 with temporary venous pacemakers.

answer: @entity5


abstract: Prognostic factors in @entity3 are related to many variables that must be evaluated according to the different subtypes. The International League of Associations of Rheumatologists (ILAR) recently proposed six different categories referred to as the Durban criteria, under the eponym of @entity8 ( @entity8 ). The aim of this classification was to define homogeneous groups according to their clinical and biologic features. The prognostic factors were classified into the different categories of @entity8 . A poor outcome in the systemic form correlated with markers of disease activity, such as @entity2 , within the first 6 months. The risk of joint destruction in @entity8 correlated with the severity of @entity3 within the first 2 years. @entity3 with positive rheumatoid factor is associated with marked disability in adulthood. In a group of psoriatic @entity0 , the risk of developing @entity9 is higher in male and @entity5 27-positive @entity0 . @entity0 with @entity8 with lower limb, knee, and tarsal involvement also are at greater risk of developing @entity9 . @entity6 is a complication of @entity8 observed mainly in @entity0 with @entity8 associated with positive antinuclear antibodies in serum. Secondary amyloidosis is observed mainly in @entity0 with systemic @entity8 . The long-term outcome must be discussed according to the various therapies. Corticosteroids contribute to @entity4 and @entity1 , for which the use of @entity0 recombinant @entity7 and biphosphonates may be an option. Newer encouraging therapies such as anticytokines have been proposed for @entity0 with active disease. Autologous stem cell transplantation is being evaluated in some centers with promising results; however, it has a high rate of mortality. Further discussion regarding which @entity0 should undergo autologous stem cell transplantation is needed, as is further discussion regarding the technical adaptations necessary.

title: Prognostic factors in XXXX .

answer: @entity8


abstract: Long-term treatment of @entity0 with chronic @entity1 requires integration of many therapeutic approaches, co-operation of several professions, and regard for the views of @entity0 and relatives. This review deals with practical aspects of pharmacotherapy, psychotherapy, cognitive resp. psychological treatments, social resp. milieu therapy, rehabilitation, interventions based on the concept of @entity6 ( @entity6 ), psychoeducation and work with relatives. Continuous neuroleptic treatment is indispensable in most cases to achieve social integration. Indications for adding on antidepressants, @entity3 , @entity5 , @entity4 and other drugs are discussed, as well as treatment of negative symptoms, @entity2 and management of treatment-resistant symptoms. Psychotherapy needs to regard the possibilities of the @entity0 . In the context of a stable long-term relationship, the @entity0 is supported in experiencing himself as a subject capable of action. Effectiveness of cognitive treatments to date is limited. The best results are achieved by social skills training. Social therapy, which aims at the improvement of functional aspects of the @entity0 , is of paramount importance. Improved possibilities for work rehabilitation are contrasted by difficulties in financing long-term social rehabilitation. Interventions based on the @entity6 concept are highly effective, but are rarely used. Programs that merely convey information without targeting behaviour modification are ineffective. The functions of facilities of treatment in the community are explained, the integrative role of case-management is stressed.

title: [Long-term treatment of chronic XXXX ].

answer: @entity1


abstract: The treatments of @entity3 ( @entity3 ) were evaluated in 14 @entity0 (15 @entity2 ) with @entity1 ( @entity1 ). We compared the data of our series with the data of co-operative study (1990) on @entity3 . With regard to consciousness level (Neurological Grading, NG) and @entity2 volume, significantly more serious cases were observed in @entity3 with @entity1 than in @entity3 of the co-operative study. In @entity3 with @entity1 , mortality (40%) was significantly higher than that in @entity3 of the co-operative study. However, the mortality rate was 0%, 0%, 20%, and 100% in NG1, 2, 3, and over 4b. The mortality rate was 0% in non-surgically treated cases with 0 to 30 ml of @entity2 volume, and 0% in surgically treated cases with 10 to 50 ml of @entity2 volume. These mortality rates were equal to those of the co-operative study with the same NG, and equal to those of the co-operative study with the same @entity2 volume. With respect to functional prognosis, "good" (ADL1 and 2) resulted in 67% of non-surgically treated cases with NG1 to 2, and in 33% of surgically treated cases with NG3 to 4a. "Good" resulted in 33% of non-surgically treated cases with 0 to 30 ml of @entity2 volume, and in 40% of surgically treated cases with 10 to 50 ml of @entity2 volume. These morbidity rates were equal to those of the co-operative study with the same NG, and equal to those of the co-operative study with the same @entity2 volume. Therefore, the high mortality in @entity3 with @entity1 was suspected to be due to the fact that, in our study, there was a higher distribution of serious cases. These findings indicate that protection against enlargement of @entity2 in the acute phase may bring about improvement of prognosis in @entity3 with @entity1 .

title: [Management of XXXX in @entity0 with @entity1 ].

answer: @entity3


abstract: The treatments of @entity3 ( @entity3 ) were evaluated in 14 @entity0 (15 @entity2 ) with @entity1 ( @entity1 ). We compared the data of our series with the data of co-operative study (1990) on @entity3 . With regard to consciousness level (Neurological Grading, NG) and @entity2 volume, significantly more serious cases were observed in @entity3 with @entity1 than in @entity3 of the co-operative study. In @entity3 with @entity1 , mortality (40%) was significantly higher than that in @entity3 of the co-operative study. However, the mortality rate was 0%, 0%, 20%, and 100% in NG1, 2, 3, and over 4b. The mortality rate was 0% in non-surgically treated cases with 0 to 30 ml of @entity2 volume, and 0% in surgically treated cases with 10 to 50 ml of @entity2 volume. These mortality rates were equal to those of the co-operative study with the same NG, and equal to those of the co-operative study with the same @entity2 volume. With respect to functional prognosis, "good" (ADL1 and 2) resulted in 67% of non-surgically treated cases with NG1 to 2, and in 33% of surgically treated cases with NG3 to 4a. "Good" resulted in 33% of non-surgically treated cases with 0 to 30 ml of @entity2 volume, and in 40% of surgically treated cases with 10 to 50 ml of @entity2 volume. These morbidity rates were equal to those of the co-operative study with the same NG, and equal to those of the co-operative study with the same @entity2 volume. Therefore, the high mortality in @entity3 with @entity1 was suspected to be due to the fact that, in our study, there was a higher distribution of serious cases. These findings indicate that protection against enlargement of @entity2 in the acute phase may bring about improvement of prognosis in @entity3 with @entity1 .

title: [Management of @entity3 in @entity0 with XXXX ].

answer: @entity1


abstract: The treatments of @entity3 ( @entity3 ) were evaluated in 14 @entity0 (15 @entity2 ) with @entity1 ( @entity1 ). We compared the data of our series with the data of co-operative study (1990) on @entity3 . With regard to consciousness level (Neurological Grading, NG) and @entity2 volume, significantly more serious cases were observed in @entity3 with @entity1 than in @entity3 of the co-operative study. In @entity3 with @entity1 , mortality (40%) was significantly higher than that in @entity3 of the co-operative study. However, the mortality rate was 0%, 0%, 20%, and 100% in NG1, 2, 3, and over 4b. The mortality rate was 0% in non-surgically treated cases with 0 to 30 ml of @entity2 volume, and 0% in surgically treated cases with 10 to 50 ml of @entity2 volume. These mortality rates were equal to those of the co-operative study with the same NG, and equal to those of the co-operative study with the same @entity2 volume. With respect to functional prognosis, "good" (ADL1 and 2) resulted in 67% of non-surgically treated cases with NG1 to 2, and in 33% of surgically treated cases with NG3 to 4a. "Good" resulted in 33% of non-surgically treated cases with 0 to 30 ml of @entity2 volume, and in 40% of surgically treated cases with 10 to 50 ml of @entity2 volume. These morbidity rates were equal to those of the co-operative study with the same NG, and equal to those of the co-operative study with the same @entity2 volume. Therefore, the high mortality in @entity3 with @entity1 was suspected to be due to the fact that, in our study, there was a higher distribution of serious cases. These findings indicate that protection against enlargement of @entity2 in the acute phase may bring about improvement of prognosis in @entity3 with @entity1 .

title: [Management of @entity3 in XXXX with @entity1 ].

answer: @entity0


abstract: This report deals with a study of the effectiveness, safety, and usefulness of long-term administration of @entity5 for the improvement of cerebral blood flow and clinical symptoms in 24 @entity0 with Chronic Cerebral Circulatory Insufficiency. Cerebral blood flow was investigated quantitatively using the Patlak plot method. @entity5 was orally administered for 209 days on average. In the global improvement rating assessed on the basis of all subjective symptoms, the final improvement rate, comprising all cases showing moderate or better improvement, was 52.2%. Regarding individual symptoms, @entity4 , @entity3 , dull @entity1 , and @entity1 showed improvement rates of 30% or more. Regional cerebral blood flow (rCBF) was increased in both cerebral and cerebellar hemispheres. The global improvement rating for subjective symptoms and the delta % rCBF for every region except the cerebral hemispheres were positively correlated. However, there was no positive correlation between the global improvement rating for @entity2 symptoms and the delta % rCBF for any region. Regarding individual subjective symptoms, @entity4 showed an especially high positive correlation of above 0.7 between the improvement rating and the delta % rCBF in the left temporal lobe, basal ganglia, and cerebellum. @entity1 was observed as an adverse drug reaction in 8 of 24 @entity0 , but it disappeared with reduction of the dose or discontinuation of administration. No other severe adverse drug reactions were noticed. In summary, it was concluded that @entity5 was useful for treating chronic cerebral circulatory insufficiency.

title: [Effects of long-term administration of XXXX on chronic cerebral circulatory insufficiency--with special reference to cerebral blood flow and clinical symptoms].

answer: @entity5


abstract: BACKGROUND: Eye patching is commonly recommended for treating @entity3 . This advice seems based more on anecdotes or disease-oriented evidence theorizing that there is faster healing or less @entity1 when the eye is patched. This meta-analysis was performed to determine if eye patching is a useful treatment for @entity3 . METHODS: We conducted a comprehensive search of both MEDLINE (1966 to 1997) and Science Citation Index to locate relevant articles. We reviewed the bibliographies of included studies, and ophthalmology and primary care texts. Local ophthalmologists and authors were contacted to identify any unpublished data. Controlled trials that evaluated eye patching compared with no patching in @entity0 older than 6 years with @entity3 were considered. The outcomes of interest were healing rates and degree of @entity1 . RESULTS: Seven trials were identified for inclusion, of which five could be statistically combined. Healing rates were similar in the two groups. The summary ratios (95% confidence interval) of healing rates in the patch group as compared with the no-patch group were 0.87 (0.68 to 1.13) and 0.90 (0.75 to 1.10) at days 1 and 2, respectively. Six studies evaluated @entity1 : four found no difference and two favored not patching. No differences in complication rates were noted between the patched and nonpatched groups. CONCLUSIONS: Eye patching was not found to improve healing rates or reduce @entity1 in @entity0 with @entity3 . Given the theoretical harm of @entity2 and possible increased @entity1 , we recommend the route of harmless nonintervention in treating @entity3 .

title: Should we patch XXXX ? A meta-analysis.

answer: @entity3


abstract: Recent studies have suggested that apoptosis and @entity1 share common features in their signaling pathway and that apoptosis requires intracellular @entity4 for its mitochondrial/ @entity11 suicide cascade. The present study was, therefore, designed to examine the role of intracellular energy levels in determining the form of cell death in cardiac myocytes. Neonatal @entity0 cardiac myocytes were first incubated for 1 h in @entity3 -free medium containing @entity9 to achieve metabolic inhibition. The cells were then incubated for another 4 h in similar medium containing @entity5 and graded concentrations of @entity3 to manipulate intracellular @entity4 levels. Under @entity4 -depleting conditions, the cell death caused by @entity5 was primarily @entity1 , as determined by @entity6 kinase release and nuclear staining with @entity10 homodimer-1. However, under @entity4 -replenishing conditions, @entity5 increased the percentage of apoptotic cells, as determined by nuclear morphology and DNA fragmentation. @entity8 activation by @entity5 was also @entity4 dependent. However, loss of mitochondrial transmembrane potential (DeltaPsi(m)), @entity7 translocation, and cytochrome c release were observed in both apoptotic and @entity1 cells. Moreover, @entity2 , an inhibitor of mitochondrial permeability transition, attenuated @entity5 -induced apoptosis and @entity1 through the inhibition of DeltaPsi(m) reduction, cytochrome c release, and @entity8 activation. Our data therefore suggest that @entity5 induces cell demise through a mitochondrial death signaling pathway and that the presence of intracellular @entity4 favors a shift from @entity1 to apoptosis through caspase activation.

title: Important role of energy-dependent mitochondrial pathways in cultured XXXX cardiac myocyte apoptosis.

answer: @entity0


abstract: OBJECTIVES: To investigate whether there is a risk excess of @entity2 among Swedish workers associated with particular occupations. METHODS: The base population was made up of Swedish @entity0 (1,779,646) and @entity0 (1,101,669) who were gainfully employed at the time of the 1970 census, had also been present in the 1960 census and were still alive and older than 24 years as of 1 January, 1971. They were followed up for 19 years until the end of 1989. Age-period standardised incidence ratios were computed in a dataset linking @entity1 diagnoses from the Swedish national @entity1 register to occupational and demographic data obtained in the census of 1970. Log-linear Poisson models were fitted, allowing for geographical area. Risk estimators per occupation were also computed for workers reporting the same occupation in 1960 and 1970, a more specifically exposed group. RESULTS: There were 7,610 @entity2 reported in the study cohort, 5,391 cases in @entity0 and 2,219 in @entity0 . A relative risk of over 1.20 and statistically significant was observed in @entity0 among accountants and auditors, secretaries and typists, auctionists, non-specified rail and road transport workers, telecommunications traffic officers, telegraph and radio operators, @entity3 and other production and related work. The risk excess was confirmed in @entity0 with the same occupation in both censuses. In @entity0 , only three occupations achieved statistical significance: metal platers and coaters, truck and conveyor operators and store and warehouse workers. CONCLUSIONS: The risk excess observed in telecommunication and transport workers could be explained by electromagnetic radiation exposure. We did not find a risk excess in agricultural occupations, that has been largely documented by other study groups.

title: XXXX and occupation in Sweden.

answer: @entity2


abstract: An unconstrained loading system was developed to measure the passive envelope of joint motion in an animal model commonly used to study ligament healing and joint @entity1 . The design of the five-degree-of-freedom system allowed for unconstrained knee joint loading throughout flexion with repeated removal and reapplication of the device to a specimen. Seven New Zealand White @entity0 knees were subjected to varus, valgus, internal and @entity2 loads, and the resulting envelopes of motion were recorded using an electromagnetic tracking device. Intra-specimen reproducibility was excellent when measured in one specimen, with maximal rotational differences of 0.6 and 0.3 deg between the fourth and fifth testing cycles for the varus (VR) and valgus (VL) envelopes, respectively. Similarly, the maximal internal (INT) and @entity2 ( @entity2 ) envelope differences were 0.5 and 0.4 deg, respectively, between the fourth and fifth cycles. Good inter-animal envelope reproducibility was also observed with consistent motion pathways for each loading condition. A maximal VR-VL laxity of 17.9 +/- 2.3 deg was recorded at 95 deg flexion for the seven knees tested. The maximal INT- @entity2 laxity of 75.2 +/- 4.8 deg occurred at 50 deg flexion. Studies on measurement reproducibility of re-applying individual testing components demonstrated a maximal error of 1.2 +/- 0.7 deg. Serial removal and re-application (test-retest) of the complete measuring system to one cadaveric knee demonstrated maximal envelope differences of less than 0.7 deg for VR-VL rotation and 2.1 deg for INT- @entity2 rotation. Our results demonstrate that the measuring system is reproducible and capable of accurate evaluation of knee joint motion. Baseline in vitro data were generated on normal joint kinematics for future in-vivo studies with this system, evaluating ligament healing and disease progression in @entity1 models.

title: Design and validation of an unconstrained loading system to measure the envelope of motion in the XXXX knee joint.

answer: @entity0


abstract: The complementary DNAs (cDNA) encoding the [Trp7,Leu8]-gonadotrophin-releasing hormone (salmon-type @entity2 ; sGnRH:GeneBank accession no. u60667) and the [His5,Trp7,Tyr8]- @entity2 ( @entity3 -II-type @entity2 ; cGnRH-II: GeneBank accession no. u60668) precursor in the roach (Rutilus rutilus) were isolated and sequenced following reverse transcription and rapid amplification of cDNA ends (RACE). The s @entity2 and cGnRH-II precursor cDNAs consisted of 439 and 628 bp, and included open reading frames of 282 and 255 bp respectively. The structures of the encoded peptides were the same as GnRHs previously identified in other vertebrates. The s @entity2 and cGnRH-II precursor cDNAs, including the non-coding regions, had 88.6 and 79.9% identity respectively, to those identified in @entity4 ( @entity4 ). However, significant similarity was not observed between the non-coding regions of the @entity2 cDNAs of Cyprinidae and other fish. The presumed third exon, encoding partial sGnRH associated peptide (GAP) of roach, demonstrated significant @entity0 and @entity1 similarity with the appropriate regions in the @entity4 , but not with other species, and this may indicate functional differences of GAP between different families of fish. cGnRH-II precursor cDNAs from roach had relatively high @entity0 similarity across this @entity2 variant. Cladistic analysis classified the sGnRH and cGnRH-II precursor cDNAs into three and two groups respectively. However, the divergence between @entity0 sequences within the sGnRH variant was greater than those encoding the cGnRH-II precursors. Consistent with the consensus developed from previous studies, Northern blot analysis demonstrated that expression of sGnRH and cGnRH-II was restricted to the olfactory bulbs and midbrain of roach respectively. This work forms the basis for further study on the mechanisms by which the tapeworm, Ligula intestinalis, interacts with the pituitary-gonadal axis of its fish host.

title: Isolation and characterisation of mRNA encoding the salmon- and XXXX -II type gonadotrophin-releasing hormones in the teleost fish Rutilus rutilus (Cyprinidae).

answer: @entity3


abstract: The prognostic relevance of karyotype has been established in adult @entity2 ( @entity2 ) @entity0 treated with chemotherapy but not definitively evaluated in an allogeneic bone marrow transplantation (BMT) setting. To determine the factors affecting the outcome of allogeneic BMT for adults with precursor B-lineage @entity2 in first or second complete remission (CR), a total of 41 consecutive @entity0 with a successful karyotype were enrolled in this study. There were 21 @entity0 and 20 @entity0 with a median age of 27 (15-43) years. The distribution of @entity4 ( @entity4 ) subtypes was as follows: L1 (n = 26), L2 (n = 15). Unfavourable karyotypes (n = 12) were defined as Ph+ or t(4;11). Disease status at the time of transplant was first CR (n = 35) or second CR (n = 6). With a median follow-up of 36 months, the 3-year probabilities of relapse and @entity1 ( @entity1 ) were 36.3 +/- 8.4% and 57.3 +/- 8.4% respectively. Potential variables predicting worse relapse and @entity1 were @entity4 subtype (L2), extramedullary involvement, pre-BMT status (second CR), unfavourable karyotype and type of @entity3 ( @entity3 ). Further multivariate analysis showed that karyotype and pre-BMT status were independently associated with relapse and @entity1 . In addition, chronic @entity3 was found to be significantly associated with a lower relapse rate.

title: Influence of karyotype on outcome of allogeneic bone marrow transplantation for adults with precursor B-lineage XXXX in first or second remission.

answer: @entity2


abstract: We reviewed 11 @entity0 who had been treated between January 1986 and June 1994 for severe @entity7 by tendon transfer with microvascular free flaps. Their mean age was 5.6 years (3 to 8). Five had simultaneous tendon transfer and a microvascular free flap and six had separate operations. The mean interval between the tendon transfer and the microvascular free flap was 5.8 months (2 to 15) and the mean time between the @entity4 .6 months (2 to 21). The anterior tibial tendon was split in five of six cases. The posterior tibial tendon was used three times and the extensor digitorum longus tendon twice. The mean follow-up was 39.7 months (24 to 126). There were nine excellent and two good results. @entity1 included loosening of the transferred tendon (2), @entity3 (1) mild @entity6 (1) and @entity5 (2). We recommend tendon transfer with a microvascular free flap in @entity0 with @entity7 combined with nerve @entity2 , soft tissue and tendon.

title: Tendon transfer with a microvascular free flap for injured feet in XXXX .

answer: @entity0


abstract: Proteases are important for neoplastic invasion but a specific role for the plasminogen activator system in the progression of @entity0 to @entity3 remains unclear. Consecutive tissue cryosections of 51 @entity1 , 49 distant mucosa samples and five mucosa samples from control subjects were histopathologically analysed for @entity2 grade and tissue type, urokinase plasminogen activator levels and @entity4 ( @entity4 ) using immunosorbent methods. Plasminogen activation and urokinase-mediated proteolytic activity levels were assessed using in situ zymography. Plasminogen activation and tissue-type activator levels were lower in @entity1 than in mucosae (P < 0.001). @entity4 concentration and urokinase levels were higher in @entity1 than in mucosae (P < 0.001 and P < 0.001 respectively). In @entity1 , urokinase concentration increased in parallel with @entity4 , but only the urokinase levels correlated with the @entity2 grade (P < 0.01). Thus, the alterations in plasminogen activation correlated with @entity5 grading. In the mucosa to @entity1 , a marked decrease in tissue-type plasminogen activator occurred. In @entity1 , this decrease was accompanied by a concomitant increase in urokinase and @entity4 . The urokinase level only continued to rise in parallel with the @entity2 grade. Resulting protease-antiprotease imbalance in high-grade @entity2 may represent the phenotypic change associated with malignant transformation and invasive behaviour.

title: Alterations in plasminogen activation correlate with XXXX grading in colorectal adenomas.

answer: @entity5


abstract: INTRODUCTION: @entity3 is a rare form of @entity2 which occurs in adults and in younger @entity0 @entity1 . Among others, complex chromosome aberrations of chromosome 12 have been described in this disease. We searched for deletions of the 12p13 region as the result of these chromosome rearrangements. MATERIAL AND METHODS: Paired leukemic and non-leukemic cells were obtained from a series of 21 @entity0 suffering @entity3 . Loss of heterozygosity was searched for by microsatellite typing using a fluorescent automated laser DNA sequencer to analyze the amplification products. Proteins were analyzed by Western blot. Southern blot analysis of one @entity0 was conducted. RESULTS AND CONCLUSION: Loss of heterozygosity of the 12p13 region, including the @entity4 and @entity5 genes, was detected in nine of these 21 cases (43%). Western and Southern blot analyses of one case demonstrated a biallelic deletion which did not include @entity4 . Taken together, our results defined a minimal region of deletion of less than one Mb flanked by the markers b312C2T7 and D12S320, excluding @entity4 as a candidate gene. Deletion of the 12p13 region is thus a highly recurrent genetic event in @entity3 .

title: Recurrent molecular deletion of the 12p13 region, centromeric to @entity4 / @entity4 , in XXXX .

answer: @entity3


abstract: INTRODUCTION: @entity3 is a rare form of @entity2 which occurs in adults and in younger @entity0 @entity1 . Among others, complex chromosome aberrations of chromosome 12 have been described in this disease. We searched for deletions of the 12p13 region as the result of these chromosome rearrangements. MATERIAL AND METHODS: Paired leukemic and non-leukemic cells were obtained from a series of 21 @entity0 suffering @entity3 . Loss of heterozygosity was searched for by microsatellite typing using a fluorescent automated laser DNA sequencer to analyze the amplification products. Proteins were analyzed by Western blot. Southern blot analysis of one @entity0 was conducted. RESULTS AND CONCLUSION: Loss of heterozygosity of the 12p13 region, including the @entity4 and @entity5 genes, was detected in nine of these 21 cases (43%). Western and Southern blot analyses of one case demonstrated a biallelic deletion which did not include @entity4 . Taken together, our results defined a minimal region of deletion of less than one Mb flanked by the markers b312C2T7 and D12S320, excluding @entity4 as a candidate gene. Deletion of the 12p13 region is thus a highly recurrent genetic event in @entity3 .

title: Recurrent molecular deletion of the 12p13 region, centromeric to XXXX / @entity4 , in @entity3 .

answer: @entity4


abstract: INTRODUCTION: @entity3 is a rare form of @entity2 which occurs in adults and in younger @entity0 @entity1 . Among others, complex chromosome aberrations of chromosome 12 have been described in this disease. We searched for deletions of the 12p13 region as the result of these chromosome rearrangements. MATERIAL AND METHODS: Paired leukemic and non-leukemic cells were obtained from a series of 21 @entity0 suffering @entity3 . Loss of heterozygosity was searched for by microsatellite typing using a fluorescent automated laser DNA sequencer to analyze the amplification products. Proteins were analyzed by Western blot. Southern blot analysis of one @entity0 was conducted. RESULTS AND CONCLUSION: Loss of heterozygosity of the 12p13 region, including the @entity4 and @entity5 genes, was detected in nine of these 21 cases (43%). Western and Southern blot analyses of one case demonstrated a biallelic deletion which did not include @entity4 . Taken together, our results defined a minimal region of deletion of less than one Mb flanked by the markers b312C2T7 and D12S320, excluding @entity4 as a candidate gene. Deletion of the 12p13 region is thus a highly recurrent genetic event in @entity3 .

title: Recurrent molecular deletion of the 12p13 region, centromeric to @entity4 / XXXX , in @entity3 .

answer: @entity4


abstract: Considerable experience has been gained with endoluminal stent-graft techniques for the treatment of @entity3 . The inclusion of uncovered suprarenal stents eases the treatment of cases with a short, angulated, or bottlenecked proximal neck. However, few data have been published on the effect of a stent-graft crossing renal artery ostia on long-term renal function. We therefore retrospectively analyzed the influence of intra-aortic stent-grafts, including suprarenal fixation on long-term renal function. Thirty-nine @entity0 who received a Gianturco Z stent across renal artery ostia as part of a made-to-measure stent-graft treating an @entity3 were evaluated at 6 (all @entity0 ) and 30 months (15 @entity0 ) after surgery. Renal function evaluation included serum @entity4 level, @entity4 clearance using the Cockcroft-Gault formula, and renal tomography. Initial technical success was achieved in all @entity0 . There were no minor or major complications. Mean serum @entity4 levels were 1.16 +/- 0.25, 1.12 +/- 0.28, and 1.24 +/- 0.25 mg/dL before and 6 and 30 months after endoluminal stent-graft performance, respectively (P = not significant [NS]). Mean @entity4 clearances were 60.3 +/- 19.7, 63 +/- 23, and 60.6 +/- 17.5 mL/min before and 6 and 30 months after endoluminal stent-graft performance, respectively (P = NS). Only two @entity0 (5%) had a decrease in glomerular filtration rate greater than 20% at 6 months. Both @entity0 had @entity2 before endovascular grafting. Renal function was stable in all @entity0 at 30 months' follow-up. We suggest that renal function is unaffected by @entity1 with Gianturco Z stents.

title: Renal function after aortic stent-grafting including XXXX .

answer: @entity1


abstract: @entity6 ( @entity6 ) and @entity4 (NO) have been suggested to have a focal role in the regulation of placental and fetal growth. @entity3 (CsA) has been shown to strongly modulate @entity6 and NO synthesis and thus has the potential to affect fetal growth and maternal state. Eleven CsA-treated female kidney transplant recipients were recruited. Fourteen healthy pregnant @entity0 served as controls. Placental expression of @entity6 and tissue factor (TF) was evaluated by in situ hybridization, and @entity7 ( @entity7 ) was evaluated by staining with the reduced form of @entity5 ( @entity5 )-diaphorase and in situ hybridization. Kidney transplant recipients showed a marked reduction in @entity5 -diaphorase staining, as well as endothelial constitutive @entity7 ( @entity8 ) messenger RNA, whereas inducible @entity7 expression was unchanged. Normal placenta showed a strong positive @entity6 signal along the endothelium of uteroplacental arteries within the basal plate, which increased markedly in decidua of transplant recipients. Thus, transplant recipients showed a remarkable alteration in @entity6 / @entity8 balance without alteration in fetal growth or maternal renal function. Next, we explored the state of placental endothelial cell activation downstream from vasoactive factors by evaluating TF gene expression. Transplant recipients did not show modification of TF transcript compared with healthy pregnant @entity0 . CsA potently affected the placental @entity6 / @entity8 vasoactive balance. Nevertheless, newborns from transplant recipient mothers were appropriate for gestational age, and transplant recipients did not show systemic @entity2 or impending @entity1 . It is suggested that CsA may blunt the activation of endothelial cells and priming of endothelial-derived substances, which possibly lie downstream from the cited vasoactive agents.

title: Placental imbalance of vasoactive factors does not affect pregnancy outcome in @entity0 treated with XXXX after transplantation.

answer: @entity3


abstract: @entity6 ( @entity6 ) and @entity4 (NO) have been suggested to have a focal role in the regulation of placental and fetal growth. @entity3 (CsA) has been shown to strongly modulate @entity6 and NO synthesis and thus has the potential to affect fetal growth and maternal state. Eleven CsA-treated female kidney transplant recipients were recruited. Fourteen healthy pregnant @entity0 served as controls. Placental expression of @entity6 and tissue factor (TF) was evaluated by in situ hybridization, and @entity7 ( @entity7 ) was evaluated by staining with the reduced form of @entity5 ( @entity5 )-diaphorase and in situ hybridization. Kidney transplant recipients showed a marked reduction in @entity5 -diaphorase staining, as well as endothelial constitutive @entity7 ( @entity8 ) messenger RNA, whereas inducible @entity7 expression was unchanged. Normal placenta showed a strong positive @entity6 signal along the endothelium of uteroplacental arteries within the basal plate, which increased markedly in decidua of transplant recipients. Thus, transplant recipients showed a remarkable alteration in @entity6 / @entity8 balance without alteration in fetal growth or maternal renal function. Next, we explored the state of placental endothelial cell activation downstream from vasoactive factors by evaluating TF gene expression. Transplant recipients did not show modification of TF transcript compared with healthy pregnant @entity0 . CsA potently affected the placental @entity6 / @entity8 vasoactive balance. Nevertheless, newborns from transplant recipient mothers were appropriate for gestational age, and transplant recipients did not show systemic @entity2 or impending @entity1 . It is suggested that CsA may blunt the activation of endothelial cells and priming of endothelial-derived substances, which possibly lie downstream from the cited vasoactive agents.

title: Placental imbalance of vasoactive factors does not affect pregnancy outcome in XXXX treated with @entity3 after transplantation.

answer: @entity0


abstract: OBJECTIVE: Primary Sj  @entity2 ( @entity2 ) may lead to @entity4 ( @entity4 ) and @entity1 in certain @entity0 . We sought to determine the incidence and predictors of adverse long-term outcomes to achieve a rational predictive classification of the syndrome. METHODS: Predictive modeling was performed in a cohort of 723 consecutive @entity0 with primary @entity2 (587 newly diagnosed [incident] cases and 136 prevalent cases). RESULTS: During 4,384 @entity0 -years of followup, we recorded 39 deaths (7 due to @entity3 ) and 38 diagnoses of @entity4 . The standardized mortality ratio was 1.15 (95% confidence interval [95% CI] 0.86-1.73) compared with the general population of Greece. In incident cases, the probability of @entity4 was 2.6% at 5 years and 3.9% at 10 years. Mortality rates were significantly higher in @entity0 with low C4 levels at the first study visit (hazard ratio [HR] 4.39, 95% CI 2.18-8.83). @entity4 was independently predicted by the presence of @entity5 (HR 5.21, 95% CI 1.76-15.4), palpable @entity6 (HR 4.16, 95% CI 1.65-10.5), and low C4 levels (HR 2.40, 95% CI 0.99-5.83) at the first study visit. All @entity0 who eventually developed @entity3 resulting in @entity1 during the followup period had either low C4 levels or palpable @entity6 at the first study visit. Training-validation split-cohort modeling confirmed the predictive importance of low C4 levels and palpable @entity6 , both of which were present in 20.9% of @entity0 at their first visit. CONCLUSIONS: In @entity0 with primary @entity2 , 1 in 5 deaths is attributable to @entity3 . The presence of palpable @entity6 and low C4 levels at the first visit adequately distinguishes high-risk @entity0 (type I primary @entity2 ) from @entity0 with an uncomplicated disease course (type II [low-risk] primary @entity2 ).

title: Long-term risk of mortality and XXXX and predictive classification of primary Sj  @entity2 .

answer: @entity4


abstract: OBJECTIVE: Primary Sj  @entity2 ( @entity2 ) may lead to @entity4 ( @entity4 ) and @entity1 in certain @entity0 . We sought to determine the incidence and predictors of adverse long-term outcomes to achieve a rational predictive classification of the syndrome. METHODS: Predictive modeling was performed in a cohort of 723 consecutive @entity0 with primary @entity2 (587 newly diagnosed [incident] cases and 136 prevalent cases). RESULTS: During 4,384 @entity0 -years of followup, we recorded 39 deaths (7 due to @entity3 ) and 38 diagnoses of @entity4 . The standardized mortality ratio was 1.15 (95% confidence interval [95% CI] 0.86-1.73) compared with the general population of Greece. In incident cases, the probability of @entity4 was 2.6% at 5 years and 3.9% at 10 years. Mortality rates were significantly higher in @entity0 with low C4 levels at the first study visit (hazard ratio [HR] 4.39, 95% CI 2.18-8.83). @entity4 was independently predicted by the presence of @entity5 (HR 5.21, 95% CI 1.76-15.4), palpable @entity6 (HR 4.16, 95% CI 1.65-10.5), and low C4 levels (HR 2.40, 95% CI 0.99-5.83) at the first study visit. All @entity0 who eventually developed @entity3 resulting in @entity1 during the followup period had either low C4 levels or palpable @entity6 at the first study visit. Training-validation split-cohort modeling confirmed the predictive importance of low C4 levels and palpable @entity6 , both of which were present in 20.9% of @entity0 at their first visit. CONCLUSIONS: In @entity0 with primary @entity2 , 1 in 5 deaths is attributable to @entity3 . The presence of palpable @entity6 and low C4 levels at the first visit adequately distinguishes high-risk @entity0 (type I primary @entity2 ) from @entity0 with an uncomplicated disease course (type II [low-risk] primary @entity2 ).

title: Long-term risk of mortality and @entity4 and predictive classification of primary Sj  XXXX .

answer: @entity2


abstract: BACKGROUND: Hepatic metastases from @entity3 frequently recur after resection and hepatic micrometastases most likely are important in the development of such recurrences. The objectives of the current study were to assess the feasibility of the immunohistochemical detection of hepatic micrometastases from @entity3 and to determine their clinical significance. METHODS: Fifty-three @entity0 underwent curative hepatic resection for @entity3 metastases. Multiple tissue sections were cut from the advancing margin of the largest hepatic @entity1 in each @entity0 and were stained with an antibody against @entity5 to detect hepatic micrometastases, which were defined as discrete microscopic @entity2 surrounding the dominant @entity1 . RESULTS: Normal hepatocytes and intrahepatic bile duct epithelia stained negative for @entity5 in all @entity0 , whereas the largest @entity4 stained positive in 46 @entity0 (86.8%). Among the 46 @entity0 with @entity4 that were positive for @entity5 , hepatic micrometastases were found immunohistochemically in 32 @entity0 (69.6%). The presence of hepatic micrometastases was associated with a larger number of macroscopic hepatic metastases (P = 0.047) and @entity0 with hepatic micrometastases were found to demonstrate a higher probability of intrahepatic recurrence (P = 0.003) compared with those @entity0 without hepatic micrometastases. In addition, @entity0 with hepatic micrometastases demonstrated a worse survival (10-year survival rate of 21.9%) compared with those @entity0 without hepatic micrometastases (10-year survival rate of 64.3%) (P = 0.017). CONCLUSIONS: Immunohistochemical detection of hepatic micrometastases is feasible in @entity0 with @entity3 . Hepatic micrometastasis indicates widespread hepatic involvement and thus predicts an increased risk of intrahepatic recurrence after hepatic resection and a poorer @entity0 prognosis.

title: Immunohistochemically detected hepatic micrometastases predict a high risk of intrahepatic recurrence after resection of XXXX .

answer: @entity3


abstract: AIM: To determine by morphometry if pleural biopsies with the histopathological diagnosis of "non-specific @entity7 ", malignant, and @entity5 could be distinguished morphologically from those with truly non-specific disease. METHODS: Each pleural biopsy was reviewed taking into account three compartments of reference: the visceral/parietal mesothelial compartment, the submesothelial screen compartment, and the submesothelial adipose tissue compartment. Normal connective tissue, granulation tissue, fibrocellular proliferation, fibrin, polymorphonuclear cells, mononuclear cells, and mesothelial cells were measured using conventional point counting procedures in terms of the fractional area occupied by each parameter within each compartment of reference. Ranking was carried out on 164 @entity0 , based on their diagnosis: chronic non-specific disease (n = 57), @entity5 (n = 27), @entity1 (n = 58), and conditions associated with transudative effusions (n = 22). RESULTS: Stepwise discriminant analysis of the resulting data showed that biopsies from @entity0 with @entity5 , @entity4 could be distinguished between themselves and normal cases. Statistical differences among the four groups were observed for eight morphometric parameters related to components of @entity2 and extension throughout the three pleural anatomical compartments. A robust discriminant function permitted an adequate classification of the three groups of disease in 88.41% of the cases. Pleural biopsies with fibrin incorporated within granulation tissue on the submesothelial screen compartment showed 100% specificity for @entity0 with @entity5 , while mononuclear cells in a band-like infiltrate on the submesothelial adipose tissue compartment showed 93.1% specificity for @entity0 with @entity1 . The truly non-specific @entity7 was characterised by deposits of fibrin in the subpleural compartment and discrete signs of @entity2 and reparatory @entity3 on the submesothelial screen. CONCLUSIONS: Morphometric analysis of pleural biopsies may be a useful supplementary histological procedure to support the diagnosis of @entity6 and @entity1 .

title: Quantitation in inflammatory pleural disease to distinguish XXXX and paramalignant from chronic non-specific @entity7 .

answer: @entity5


abstract: AIM: To determine by morphometry if pleural biopsies with the histopathological diagnosis of "non-specific @entity7 ", malignant, and @entity5 could be distinguished morphologically from those with truly non-specific disease. METHODS: Each pleural biopsy was reviewed taking into account three compartments of reference: the visceral/parietal mesothelial compartment, the submesothelial screen compartment, and the submesothelial adipose tissue compartment. Normal connective tissue, granulation tissue, fibrocellular proliferation, fibrin, polymorphonuclear cells, mononuclear cells, and mesothelial cells were measured using conventional point counting procedures in terms of the fractional area occupied by each parameter within each compartment of reference. Ranking was carried out on 164 @entity0 , based on their diagnosis: chronic non-specific disease (n = 57), @entity5 (n = 27), @entity1 (n = 58), and conditions associated with transudative effusions (n = 22). RESULTS: Stepwise discriminant analysis of the resulting data showed that biopsies from @entity0 with @entity5 , @entity4 could be distinguished between themselves and normal cases. Statistical differences among the four groups were observed for eight morphometric parameters related to components of @entity2 and extension throughout the three pleural anatomical compartments. A robust discriminant function permitted an adequate classification of the three groups of disease in 88.41% of the cases. Pleural biopsies with fibrin incorporated within granulation tissue on the submesothelial screen compartment showed 100% specificity for @entity0 with @entity5 , while mononuclear cells in a band-like infiltrate on the submesothelial adipose tissue compartment showed 93.1% specificity for @entity0 with @entity1 . The truly non-specific @entity7 was characterised by deposits of fibrin in the subpleural compartment and discrete signs of @entity2 and reparatory @entity3 on the submesothelial screen. CONCLUSIONS: Morphometric analysis of pleural biopsies may be a useful supplementary histological procedure to support the diagnosis of @entity6 and @entity1 .

title: Quantitation in inflammatory pleural disease to distinguish @entity5 and paramalignant from chronic non-specific XXXX .

answer: @entity7


abstract: AIM: To investigate the presence of genetic instability in @entity4 of the stomach. METHODS: Fifteen cases of @entity2 with a background of @entity5 were studied by microsatellite assay at nine loci. Altered metaplastic mucosa was microdissected, reconstructed topographically, and examined immunohistochemically with an anti- @entity3 antibody, comparing its positive area with foci of microsatellite instability in each individual. RESULTS: Alterations at one or more loci were observed in seven of 15 @entity0 (46.7%) and four of 15 intestinal metaplasias (26.7%). Two cases of replication error positive phenotype had no microsatellite alterations in their metaplastic mucosa. All the microsatellite alterations in the metaplastic mucosa were @entity5 around the respective @entity0 . Moreover, in one case, an identical pattern of microsatellite alteration was detected in the @entity0 tissue and in the adjacent metaplastic mucosa, suggesting the sequential development of @entity2 from @entity5 . Frequent alteration was found at the locus D1S191 (1q), indicating that this locus might be altered early in the development of @entity2 . No significant association between microsatellite instability and @entity3 immunoreactivity was observed in the cases examined. CONCLUSION: These results indicate that microsatellite instability may be an early event in @entity1 , especially in @entity0 .

title: Altered microsatellites in incomplete-type @entity5 adjacent to primary XXXX .

answer: @entity2


abstract: AIM: To investigate the presence of genetic instability in @entity4 of the stomach. METHODS: Fifteen cases of @entity2 with a background of @entity5 were studied by microsatellite assay at nine loci. Altered metaplastic mucosa was microdissected, reconstructed topographically, and examined immunohistochemically with an anti- @entity3 antibody, comparing its positive area with foci of microsatellite instability in each individual. RESULTS: Alterations at one or more loci were observed in seven of 15 @entity0 (46.7%) and four of 15 intestinal metaplasias (26.7%). Two cases of replication error positive phenotype had no microsatellite alterations in their metaplastic mucosa. All the microsatellite alterations in the metaplastic mucosa were @entity5 around the respective @entity0 . Moreover, in one case, an identical pattern of microsatellite alteration was detected in the @entity0 tissue and in the adjacent metaplastic mucosa, suggesting the sequential development of @entity2 from @entity5 . Frequent alteration was found at the locus D1S191 (1q), indicating that this locus might be altered early in the development of @entity2 . No significant association between microsatellite instability and @entity3 immunoreactivity was observed in the cases examined. CONCLUSION: These results indicate that microsatellite instability may be an early event in @entity1 , especially in @entity0 .

title: Altered microsatellites in incomplete-type XXXX adjacent to primary @entity2 .

answer: @entity5


abstract: The Swedish Knee Arthroplasty Register has data on 4,381 primary operations performed 1985-1995 for @entity2 . Of these, 192 were performed with unicompartmental prostheses and 4143 with tricompartmental. 77% were @entity0 and the mean age was 66 years. There were 126 first, 20 second, and 1 third revision in tricompartmental arthroplasties, mainly for loosening, @entity1 . There were 38 first, 3 second, and 1 third revision in unicompartmental arthroplasties, mainly for progression of @entity2 and loosening. Cumulative revision rates (Kaplan-Meier) were calculated. Tricompartmental knees had a 10-year cumulative revision rate of 5% and uni-knees 25%. @entity0 treated before 1990, @entity0 and @entity0 younger than 55 had higher revision rates than @entity0 treated after 1990, @entity0 and older @entity0 , respectively. Cemented tibial components resulted in lower revision rates than uncemented ones. There was no significant difference in revision rates between patellar replaced and unreplaced knees or between the 9 commonest implant types.

title: Knee arthroplasty in XXXX . A report from the Swedish Knee Arthroplasty Register on 4,381 primary operations 1985-1995.

answer: @entity2


abstract: Optimal management of @entity2 with dual chamber pacemakers requires proper performance of @entity4 ( @entity4 ). The aim of this study was to develop a reliable technique to test the @entity4 function by using an external electronic device capable of mimicking the occurrence of @entity2 ( @entity2 Simulator [SAS]). The SAS delivers low voltage pulse trains (200 mV, 20 ms) through two skin electrodes. Each pulse train lasts 15 seconds and starts synchronously with a pacing pulse of the implanted pacemaker to avoid interference from the operator. The pulse train rate is set at 350, 250, and 160 beats/min to simulate AF, @entity3 , and @entity1 ( @entity1 ), respectively. Thirty-five @entity0 implanted with Vitatron pacemakers, whose @entity4 system has been previously validated, were enrolled. Atrial and ventricular sensing were programmed in unipolar mode at 0.5 mV and in bipolar mode at > 2 mV, respectively. All pulses from the SAS were detected by the atrial channel at an amplitude ranging from 1 to 3 mV. The test proved to be safe and reliable at rest and during exercise. @entity4 occurred immediately at onset or at offset of @entity2 , and no adverse interference on pacemaker function was seen from the SAS. In conclusion, the described technique and the SAS are safe and reliable for @entity0 and pacemaker function and can be proposed as a useful method to verify proper performance of @entity4 function irrespective of the type of implanted devices.

title: How to test mode switching in pacemakers implanted in XXXX : the MOST study.

answer: @entity0


abstract: @entity1 is a classic sign of @entity4 . However, there are limited data regarding its prevalence in cirrhotic @entity0 without overt @entity4 . We assessed the characteristics of sleep in @entity3 using a sleep questionnaire (n = 44) and actigraphy (n = 20). The results were compared with those of subjects with @entity7 and those of healthy controls. Presence of subclinical @entity4 , chronotypology profile, and individual's affective state were also analyzed. The questionnaire indicated an elevated number of cirrhotic @entity0 (47.7%) and @entity0 with @entity7 (38.6%) who complained of unsatisfactory sleep compared with healthy controls (4.5%, P < .01). @entity1 in cirrhotic @entity0 with unsatisfactory sleep. The @entity1 in @entity3 was not associated with clinical parameters nor with @entity2 . Cirrhotic subjects and @entity0 with @entity7 with unsatisfactory sleep showed higher scores for @entity8 and @entity6 , raising the possibility that the effects of @entity5 may underlie the pathogenesis of @entity1 . However, in contrast to @entity7 , unsatisfactory sleep in @entity3 was associated with delayed bedtime, delayed wake-up time, and evening chronotypology. In conclusion, a @entity1 is frequent in cirrhotic @entity0 without @entity4 and may be related to abnormalities of the circadian timekeeping system.

title: High prevalence of @entity1 in XXXX .

answer: @entity3


abstract: @entity1 is a classic sign of @entity4 . However, there are limited data regarding its prevalence in cirrhotic @entity0 without overt @entity4 . We assessed the characteristics of sleep in @entity3 using a sleep questionnaire (n = 44) and actigraphy (n = 20). The results were compared with those of subjects with @entity7 and those of healthy controls. Presence of subclinical @entity4 , chronotypology profile, and individual's affective state were also analyzed. The questionnaire indicated an elevated number of cirrhotic @entity0 (47.7%) and @entity0 with @entity7 (38.6%) who complained of unsatisfactory sleep compared with healthy controls (4.5%, P < .01). @entity1 in cirrhotic @entity0 with unsatisfactory sleep. The @entity1 in @entity3 was not associated with clinical parameters nor with @entity2 . Cirrhotic subjects and @entity0 with @entity7 with unsatisfactory sleep showed higher scores for @entity8 and @entity6 , raising the possibility that the effects of @entity5 may underlie the pathogenesis of @entity1 . However, in contrast to @entity7 , unsatisfactory sleep in @entity3 was associated with delayed bedtime, delayed wake-up time, and evening chronotypology. In conclusion, a @entity1 is frequent in cirrhotic @entity0 without @entity4 and may be related to abnormalities of the circadian timekeeping system.

title: High prevalence of XXXX in @entity3 .

answer: @entity1


abstract: @entity4 is one of the most effective treatments for @entity0 through its ability to antagonize @entity3 -dependent growth by binding @entity3 receptors (ERs) and inhibiting breast epithelial cell proliferation. However, @entity4 has estrogenic agonist effects in other tissues such as bone and endometrium because of liganded ER-activating target genes in these different cell types. Several novel antiestrogen compounds have been developed that are also selective ER modulators (SERMs) but that have a reduced agonist profile on breast and gynecological tissues. These SERMs offer the potential for enhanced efficacy and reduced @entity2 compared with @entity4 . In @entity0 clinical data exist for three first-generation SERMs ( @entity6 , @entity7 , @entity10 ), which are related to the @entity9 structure of @entity4 . In Phase II trials in a total of 263 @entity1 resistant to @entity4 , the median objective response rate to these SERMs was only 5% (range, 0-15%), with stable disease for > or =6 months in an additional 18% (range, 9-23%). As first-line therapy for @entity0 , the median response rate was 31% (range, 20-68%) with a median time to progression of 7 months. Randomized Phase III trials for @entity6 and @entity10 in more than 1500 @entity1 showed no significant difference compared with @entity4 . Fewer clinical data exist for the structurally distinct second- and third-generation SERMs ( @entity5 , @entity8 , @entity11 , and @entity12 ), although a similarly low median response rate of 6% (range, 0-14%) was seen in Phase II trials in @entity4 -resistant @entity1 . It remains unclear whether any clinical advantage exists for second- and third-generation SERMs over @entity4 as first-line therapy. With the emergence of potent aromatase inhibitors (AIs) that are superior to @entity4 , the clinical questions in advanced disease have shifted to which antiestrogen (including SERMs) may be effective following failure of AIs, and whether any merit exists for combined AI/SERM therapy. The main advantage for SERM therapy probably remains in early stage-disease (adjuvant therapy or prevention), in which the estrogenic effects on bone and reduced gynecological side effects may prove more beneficial than either @entity4 or AI. The issue is whether the current clinical data for SERMs in @entity0 are sufficiently strong to encourage that further development.

title: Endocrine manipulation in XXXX : recent advances with SERM therapies.

answer: @entity0


abstract: The combined therapeutic effect of cytokine-producing @entity0 cell vaccines and local radiotherapy was studied in a @entity2 @entity1 261 (GI261) @entity7 model. @entity7 -bearing @entity2 were treated with cytokine ( @entity3 , @entity6 , @entity10 , @entity9 , @entity5 , @entity11 , LT) producing vaccines made by in vitro transduction of GI261 cells with the corresponding adenoviral vectors. Vaccines producing either @entity3 or @entity9 cured 20-40% of mice. The antitumor effect strongly depended on the secreted cytokine level. Vaccination therapy induced specific activation of cytotoxic T lymphocytes measured by cell-mediated @entity4 assay. @entity7 were heavily infiltrated by @entity8 + lymphocytes after treatment with @entity3 - or @entity9 -secreting cells. @entity9 vaccination induced moderate CD8+ infiltration, as well. Depleting either @entity8 + or CD8+ lymphocyte subsets abolished the anticancer effect of @entity9 -expressing cells. Strong synergism was observed by combining cytokine vaccination ( @entity9 , @entity3 , IL-12) with @entity0 irradiation: about 80-100% of the @entity1 -bearing @entity2 was cured. The high efficiency of combined treatment was maintained even under suboptimal conditions when neither of the modalities cured any of the @entity2 alone. This suggests that vaccination therapy might open a new potential in the clinical treatment of high-grade @entity1 when applied as adjuvant to existing treatment modalities.

title: @entity0 irradiation augments the antitumor effect of cytokine-producing autologous @entity0 cell vaccines in a @entity2 XXXX model.

answer: @entity1


abstract: The combined therapeutic effect of cytokine-producing @entity0 cell vaccines and local radiotherapy was studied in a @entity2 @entity1 261 (GI261) @entity7 model. @entity7 -bearing @entity2 were treated with cytokine ( @entity3 , @entity6 , @entity10 , @entity9 , @entity5 , @entity11 , LT) producing vaccines made by in vitro transduction of GI261 cells with the corresponding adenoviral vectors. Vaccines producing either @entity3 or @entity9 cured 20-40% of mice. The antitumor effect strongly depended on the secreted cytokine level. Vaccination therapy induced specific activation of cytotoxic T lymphocytes measured by cell-mediated @entity4 assay. @entity7 were heavily infiltrated by @entity8 + lymphocytes after treatment with @entity3 - or @entity9 -secreting cells. @entity9 vaccination induced moderate CD8+ infiltration, as well. Depleting either @entity8 + or CD8+ lymphocyte subsets abolished the anticancer effect of @entity9 -expressing cells. Strong synergism was observed by combining cytokine vaccination ( @entity9 , @entity3 , IL-12) with @entity0 irradiation: about 80-100% of the @entity1 -bearing @entity2 was cured. The high efficiency of combined treatment was maintained even under suboptimal conditions when neither of the modalities cured any of the @entity2 alone. This suggests that vaccination therapy might open a new potential in the clinical treatment of high-grade @entity1 when applied as adjuvant to existing treatment modalities.

title: XXXX irradiation augments the antitumor effect of cytokine-producing autologous @entity0 cell vaccines in a @entity2 @entity1 model.

answer: @entity0


abstract: The combined therapeutic effect of cytokine-producing @entity0 cell vaccines and local radiotherapy was studied in a @entity2 @entity1 261 (GI261) @entity7 model. @entity7 -bearing @entity2 were treated with cytokine ( @entity3 , @entity6 , @entity10 , @entity9 , @entity5 , @entity11 , LT) producing vaccines made by in vitro transduction of GI261 cells with the corresponding adenoviral vectors. Vaccines producing either @entity3 or @entity9 cured 20-40% of mice. The antitumor effect strongly depended on the secreted cytokine level. Vaccination therapy induced specific activation of cytotoxic T lymphocytes measured by cell-mediated @entity4 assay. @entity7 were heavily infiltrated by @entity8 + lymphocytes after treatment with @entity3 - or @entity9 -secreting cells. @entity9 vaccination induced moderate CD8+ infiltration, as well. Depleting either @entity8 + or CD8+ lymphocyte subsets abolished the anticancer effect of @entity9 -expressing cells. Strong synergism was observed by combining cytokine vaccination ( @entity9 , @entity3 , IL-12) with @entity0 irradiation: about 80-100% of the @entity1 -bearing @entity2 was cured. The high efficiency of combined treatment was maintained even under suboptimal conditions when neither of the modalities cured any of the @entity2 alone. This suggests that vaccination therapy might open a new potential in the clinical treatment of high-grade @entity1 when applied as adjuvant to existing treatment modalities.

title: @entity0 irradiation augments the antitumor effect of cytokine-producing autologous XXXX cell vaccines in a @entity2 @entity1 model.

answer: @entity0


abstract: The combined therapeutic effect of cytokine-producing @entity0 cell vaccines and local radiotherapy was studied in a @entity2 @entity1 261 (GI261) @entity7 model. @entity7 -bearing @entity2 were treated with cytokine ( @entity3 , @entity6 , @entity10 , @entity9 , @entity5 , @entity11 , LT) producing vaccines made by in vitro transduction of GI261 cells with the corresponding adenoviral vectors. Vaccines producing either @entity3 or @entity9 cured 20-40% of mice. The antitumor effect strongly depended on the secreted cytokine level. Vaccination therapy induced specific activation of cytotoxic T lymphocytes measured by cell-mediated @entity4 assay. @entity7 were heavily infiltrated by @entity8 + lymphocytes after treatment with @entity3 - or @entity9 -secreting cells. @entity9 vaccination induced moderate CD8+ infiltration, as well. Depleting either @entity8 + or CD8+ lymphocyte subsets abolished the anticancer effect of @entity9 -expressing cells. Strong synergism was observed by combining cytokine vaccination ( @entity9 , @entity3 , IL-12) with @entity0 irradiation: about 80-100% of the @entity1 -bearing @entity2 was cured. The high efficiency of combined treatment was maintained even under suboptimal conditions when neither of the modalities cured any of the @entity2 alone. This suggests that vaccination therapy might open a new potential in the clinical treatment of high-grade @entity1 when applied as adjuvant to existing treatment modalities.

title: @entity0 irradiation augments the antitumor effect of cytokine-producing autologous @entity0 cell vaccines in a XXXX @entity1 model.

answer: @entity2


abstract: Several animal models have been designed in the past to analyze the pathophysiology and management of @entity0 , very few of which were intrauterine. Those that were interuterine had problems with either a short gestation or limited availability that prevented most researchers from using them in treatment analysis. We desired to create a biologically sound intrauterine model of @entity0 , using an animal with a long gestation and an early calvarial bone formation, which was easy to manipulate in utero, that could be created by any researcher studying this disorder. Using biologic data available regarding growth factors thought to be involved in bone growth and cranial suture closure, we developed a new in utero fetal lamb model for the study of @entity0 . Ten 70-day gestation fetal @entity1 (term gestation 140 days) received a midline coronal incision to expose both coronal sutures. The entire right coronal suture was then excised along with a 4-mm bony margin. In each animal, the site was packed with 25 mg of demineralized @entity1 bone powder augmented with 50 microg of @entity4 ( @entity4 ) and 1 microg of poly-transforming growth factor-beta. The scalp was closed, and the @entity1 were returned to the uterus until either 90 or 140 days of gestation. Complete fusion of the right coronal suture occurred in all fetuses by 90 days gestation. In every animal, right-sided frontal bone flattening and supraorbital rim elevation were evident. Histologic analysis showed bony @entity3 at the suture site without evidence of suture regeneration. By 140 days, this isolated suture fusion led to marked @entity2 including right supraorbital rim elevation, significant frontal bone flattening, a decrease in the anterior-posterior length of the cranial vault, and flattening of the cranial base. In conclusion, we have developed a new model for the study of the secondary effects induced by the process of cranial suture fusion, which produces abnormalities seen in naturally occurring cases of isolated right coronal suture @entity3 . In addition, this model confirms that isolated coronal suture fusion alone can lead to the multiple cranial and @entity2 seen with this disorder, even in the absence of associated cranial base suture fusions.

title: A new in utero XXXX model for unilateral coronal craniosynostosis.

answer: @entity1


abstract: The purpose of this study was to examine the effect of @entity6 on cardiac function and neurohumoral factors ( @entity5 , @entity4 , @entity3 ) after reperfused @entity1 without @entity2 (Killip class I). On the first day after @entity1 following reperfusion therapy @entity0 were randomly assigned to @entity6 treatment (group 1, n=33) or no treatment (group 2, n=39). We then performed echocardiographic examinations on the @entity0 and measured heart rate, mean blood pressure and neurohormones ( @entity5 , @entity4 and @entity3 ). Follow-up evaluations of echocardiography were performed at 4 and 12 weeks and of neurohormones at 1 and 4 weeks after @entity1 . The highest peaks of plasma @entity5 , @entity4 , and @entity3 levels were observed before treatment and decreased with time in both groups. After 4 weeks the level of plasma @entity5 in the @entity6 treatment group was lower than in the no treatment group [55+/-3 pg/mL vs 85+/-5 pg/mL (P < 0.05)]. Other neurohormones did not differ between groups. Fractional shortening (FS) and ejection fraction (EF)improved after @entity1 in both groups, but significantly more in the @entity6 group (P < 0.05) after 12 weeks of treatment. Changes in @entity5 correlated significantly with changes in left ventricular end systolic volumes, FS and EF. In this study, @entity6 significantly improved systolic function and reduced the level of plasma @entity5 after @entity1 , which suggest that @entity6 may have a beneficial effect on @entity1 without @entity2 .

title: Effect of @entity6 on cardiac function assessed by echocardiography and neurohumoral factors after reperfused @entity1 without XXXX .

answer: @entity2


abstract: The purpose of this study was to examine the effect of @entity6 on cardiac function and neurohumoral factors ( @entity5 , @entity4 , @entity3 ) after reperfused @entity1 without @entity2 (Killip class I). On the first day after @entity1 following reperfusion therapy @entity0 were randomly assigned to @entity6 treatment (group 1, n=33) or no treatment (group 2, n=39). We then performed echocardiographic examinations on the @entity0 and measured heart rate, mean blood pressure and neurohormones ( @entity5 , @entity4 and @entity3 ). Follow-up evaluations of echocardiography were performed at 4 and 12 weeks and of neurohormones at 1 and 4 weeks after @entity1 . The highest peaks of plasma @entity5 , @entity4 , and @entity3 levels were observed before treatment and decreased with time in both groups. After 4 weeks the level of plasma @entity5 in the @entity6 treatment group was lower than in the no treatment group [55+/-3 pg/mL vs 85+/-5 pg/mL (P < 0.05)]. Other neurohormones did not differ between groups. Fractional shortening (FS) and ejection fraction (EF)improved after @entity1 in both groups, but significantly more in the @entity6 group (P < 0.05) after 12 weeks of treatment. Changes in @entity5 correlated significantly with changes in left ventricular end systolic volumes, FS and EF. In this study, @entity6 significantly improved systolic function and reduced the level of plasma @entity5 after @entity1 , which suggest that @entity6 may have a beneficial effect on @entity1 without @entity2 .

title: Effect of XXXX on cardiac function assessed by echocardiography and neurohumoral factors after reperfused @entity1 without @entity2 .

answer: @entity6


abstract: The purpose of this study was to examine the effect of @entity6 on cardiac function and neurohumoral factors ( @entity5 , @entity4 , @entity3 ) after reperfused @entity1 without @entity2 (Killip class I). On the first day after @entity1 following reperfusion therapy @entity0 were randomly assigned to @entity6 treatment (group 1, n=33) or no treatment (group 2, n=39). We then performed echocardiographic examinations on the @entity0 and measured heart rate, mean blood pressure and neurohormones ( @entity5 , @entity4 and @entity3 ). Follow-up evaluations of echocardiography were performed at 4 and 12 weeks and of neurohormones at 1 and 4 weeks after @entity1 . The highest peaks of plasma @entity5 , @entity4 , and @entity3 levels were observed before treatment and decreased with time in both groups. After 4 weeks the level of plasma @entity5 in the @entity6 treatment group was lower than in the no treatment group [55+/-3 pg/mL vs 85+/-5 pg/mL (P < 0.05)]. Other neurohormones did not differ between groups. Fractional shortening (FS) and ejection fraction (EF)improved after @entity1 in both groups, but significantly more in the @entity6 group (P < 0.05) after 12 weeks of treatment. Changes in @entity5 correlated significantly with changes in left ventricular end systolic volumes, FS and EF. In this study, @entity6 significantly improved systolic function and reduced the level of plasma @entity5 after @entity1 , which suggest that @entity6 may have a beneficial effect on @entity1 without @entity2 .

title: Effect of @entity6 on cardiac function assessed by echocardiography and neurohumoral factors after reperfused XXXX without @entity2 .

answer: @entity1


abstract: UNASSIGNED: Objectives Progestogen-only pills (POPs) are safer with respect to cardiovascular risks than contraceptives containing @entity1 . Despite the increased contraceptive efficacy of a @entity6 -only pill compared with a traditional POP, POPs are still not widely used due to an unpredictable @entity2 pattern. A new POP containing 4 mg @entity5 has been developed with a 24/4 intake regimen which may improve the @entity2 pattern. The objectives of this study were to investigate ovulation inhibition with the new @entity5 -only pill in comparison with the @entity6 -only pill and, in addition, to assess the effects on cervical mucus permeability and @entity2 . Methods Sixty-four healthy volunteers with proven ovulatory cycles were randomised and treated with either the @entity5 -only or the @entity6 -only pill during two 28-day cycles. Follicular diameter, endometrial thickness, and serum @entity0 (E2) and @entity3 concentrations were measured and Hoogland scores were determined. Additionally, cervical mucus scores, @entity2 and return of ovulation were assessed. Results Both treatments effectively inhibited ovulation. Follicular diameter, E2 levels and Hoogland scores were equal, demonstrating @entity4 . One subject in each group had a Hoogland score of 6, but the criteria for normal luteal activity were not fulfilled. In both groups, ovulation did not occur before day 9 of the post-treatment cycle. Cervical mucus permeability was suppressed in both groups. The median number of @entity2 and spotting days was lower in the @entity5 group. Conclusions The new @entity5 -only pill inhibited ovulation as effectively as the @entity6 -only pill despite the 4-day hormone-free interval.

title: A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing XXXX and a new POP containing @entity5 in a 24/4 regimen.

answer: @entity6